Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Site for Phase II, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is to determine the overall response rate (ORR) of telisotuzumab vedotin in subjects with c-Met+ non-small cell lung cancer.
Adult male or female, at least 18 years old Subjects must have c-Met+ NSCLC as assessed by an AbbVie designated IHC laboratory or known documented MET gene amplification Subjects have adequate bone marrow, renal, and hepatic function Subjects are willing and able to comply with procedures required in this protocol Subjects have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Exclusion Criteria:
Subjects must not have a history of major immunologic reaction to any IgG containing agent Subjects must not have psychiatric illness/social situation that would limit compliance with the study Subjects must not have any medical condition which in the opinion of the Investigator or Therapeutic Area Medical Director (TA MD) places the subject at an unacceptably high risk for toxicities Subjects must not have received any live vaccine within 30 days of the first dose of investigational product Subjects must not have had major surgery within 21 days prior to the first dose of telisotuzumab vedotin